HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
Risk and Benefit of New Therapies

Individualization of care with careful medication selection is increasingly recognized as one of the foundations of care for diabetes, which is not a disease of "one size fits all." The amount of time spent in a condition of hyperglycemia has long been known to raise the risk of complications. Hyperglycemia can leave a negative "metabolic memory" on cells of the vasculature and target organs, encouraging the development of difficulties in the future. Despite the necessity of meeting proper glycemic targets, there is still a gap between the goals specified and the goals achieved. Failure to commence or intensify treatment in a timely manner in persons whose health is expected to improve with this intensification is referred to as clinical inertia

Committee Members
Speaker at Diabetes, Metabolism and Endocrinology 2025 - Bob Esquerre

Bob Esquerre

Esquerre Fitness Group International, United States
Speaker at Diabetes, Metabolism and Endocrinology 2025 - F Buck Willis

F Buck Willis

IUHS School of Medicine, Saint Kitts and Nevis
Speaker at Diabetes, Metabolism and Endocrinology 2025 - Wan Rosli Wan Ishak

Wan Rosli Wan Ishak

Universiti Sains Malaysia, Malaysia

Submit your abstract Today

Watsapp